The Expora Platform™

The Expora Platform™ unlocks commercialization of bacterial extracellular vesicles

Platform

A Breakthrough in Extracellular Vesicles

The Expora Platform™ overcomes critical manufacturing barriers to pave the way for promising applications of BEVs in human health:

  • Defined, precision BEV dosing via oral, inhaled, or injection ROAs

  • Scalable, GMP-ready manufacturing at 10-100 fold lower costs

  • Production from FDA-designated Generally Regarded As Safe (GRAS) probiotics studied in hundreds of clinical trials

Platform

A Breakthrough in Extracellular Vesicles

The Expora Platform™ overcomes critical manufacturing barriers to pave the way for promising applications of BEVs in human health:

  • Defined, precision BEV dosing via oral, inhaled, or injection ROAs

  • Scalable, GMP-ready manufacturing at 10-100 fold lower costs

  • Production from FDA-designated Generally Regarded As Safe (GRAS) probiotics studied in hundreds of clinical trials

Platform

A Breakthrough in Extracellular Vesicles

The Expora Platform™ overcomes critical manufacturing barriers to pave the way for promising applications of BEVs in human health:

  • Defined, precision BEV dosing via oral, inhaled, or injection ROAs

  • Scalable, GMP-ready manufacturing at 10-100 fold lower costs

  • Production from FDA-designated Generally Regarded As Safe (GRAS) probiotics studied in hundreds of clinical trials

3x

3x

3x

Potency

Potency

Potency

60x

60x

60x

Yield

Yield

Yield

10-100x

10-100x

10-100x

Lower Cost

Lower Cost

Lower Cost

Synthetic Biology Platform

The Expora Platform™ applies the power of cutting edge bioengineering technologies to rapidly design new BEV products through producer cell engineering. A product of over a decade in development and $10M of federally-funded research, our technology derisks the most critical barriers to EV development

The Expora Platform™ applies the power of synthetic biology by genetically programming non-inflammatory bacteria originally isolated from the human body for production of gut-targeted, multi-specific EV therapeutics. A product of over a decade in development and $10M of federally-funded research, our technology derisks multiple aspects of EV development.

Scalable Manufacturing

The Expora Platform™ unlocks potential for commercial scale BEV manufacturing. Our processes reduce costs 10-100x and have potential to scale to produce tens of millions of doses per year, with unmatched product quality.

Precision Medicine by Design

Expora's believes gut-targeted, multi-specific BEVs are the ideal modality to treat immune-mediated GI diseases, where conventional modalities face safety, efficacy, or delivery limitations. Our modular BEV design targets multiple immune processes underpinning numerous GI diseases, with potential to deliver designer therapeutic cargo via multiple ROAs including oral.

Partner With Us to Advance the Future of Extracellular Vesicle Therapeutics

We are seeking collaborators, funders, scientific and strategic partners who share our commitment to advancing the future of exosome therapeutics.

Get In Touch

Explore Our Pipeline

Partner With Us to Advance the Future of Extracellular Vesicle Therapeutics

We are seeking collaborators, funders, scientific and strategic partners who share our commitment to advancing the future of exosome therapeutics.

Get In Touch

Explore Our Pipeline

Partner With Us to Advance the Future of Extracellular Vesicle Therapeutics

We are seeking collaborators, funders, scientific and strategic partners who share our commitment to advancing the future of exosome therapeutics.

Get In Touch

Explore Our Pipeline